Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
As we count down the remaining days until the launch of this global event in Kraków, Poland, ADI is proud to share a message from our CEO, Paola Barbarino, and highlight some of our key speakers joining us from 24-26 April 2024.
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
In this exercept from the essay 'Providing optimal dementia support to Indigenous people in North America', from the World Alzheimer Report 2022, Jordan P Lewis (Aleut) and Kristen M Jacklin write about the need for culturally tailored dementia care in Indigenous communities in North America.
We asked some of our sponsors what inspires them to support World Alzheimer's Month as well as people living with dementia and their families.
ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.
In this press release, it is revealed that the World Alzheimer Report 2022 finds as many as 85 percent of people with dementia could be missing out on post-diagnosis care.
In this exercept from the essay 'The impact of caregiving in LGBTQ+ communities', from the World Alzheimer Report 2022, Julien Rougerie outlines the challenges of caregiving faced by the LGBTQ+ community.
In this exercept from the essay 'Living to the best of one's ability', from the World Alzheimer Report 2022, Keith Oliver shares how the support of others has helped him to navigate life since his diagnosis 11 years ago.
In this blog, Shamayne Leelawati shares how her caring journey for her father changed after COVID-19 and how it inspired her to change the narrative around post-diagnostic care.
ADI, alongside Newcastle University and the London School of Economics, is submitting an application to the WHO Expert Committee on the inclusion of anti-dementia medication and needs to hear from clinicians everywhere.